Available online 26 August 2022

Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention.

Lipoprotein(a)

Lp(a)

Biomarker

Atherosclerotic cardiovascular disease

Cut points

Cardiovascular risk

Coronary heart disease

Myocardial infarction

Stroke

Calcific valvular aortic disease

Primary prevention

Secondary prevention

Treatment

Lifestyle

Scientific statement

© 2022 National Lipid Association. Published by Elsevier Inc. All rights reserved.